8XX Stock Overview
A healthcare biotech company, develops, produces, and markets vitro diagnostic medical devices in Italy.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Ulisse Biomed S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.86 |
| 52 Week High | €1.87 |
| 52 Week Low | €0.68 |
| Beta | 0.62 |
| 11 Month Change | -8.30% |
| 3 Month Change | -13.28% |
| 1 Year Change | -45.10% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -77.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8XX | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -4.2% | -0.009% | -1.2% |
| 1Y | -45.1% | -17.6% | 9.0% |
Return vs Industry: 8XX underperformed the German Biotechs industry which returned -17.6% over the past year.
Return vs Market: 8XX underperformed the German Market which returned 9% over the past year.
Price Volatility
| 8XX volatility | |
|---|---|
| 8XX Average Weekly Movement | 13.0% |
| Biotechs Industry Average Movement | 6.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 8XX's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 8XX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 8 | Nicola Basile | www.ulissebiomed.com |
Ulisse Biomed S.p.A., a healthcare biotech company, develops, produces, and markets vitro diagnostic medical devices in Italy. The company through its Sagitta platform offers various tests, such as Ladymed/HPV Selfy for the detection of human papillomavirus (HPV); CoronaMelt, a diagnostic test for Sars- CoV-2; CoronaMelt Var, a diagnostic assay for the detection and genotyping of Sars-CoV-2 variants; and UlisseFaster, a reagent for the pre-treatment of biological samples. It provides various tests and reagents for sexually transmitted diseases and HPV.
Ulisse Biomed S.p.A. Fundamentals Summary
| 8XX fundamental statistics | |
|---|---|
| Market cap | €19.48m |
| Earnings (TTM) | -€6.97m |
| Revenue (TTM) | €420.92k |
46.3x
P/S Ratio-2.8x
P/E RatioIs 8XX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8XX income statement (TTM) | |
|---|---|
| Revenue | €420.92k |
| Cost of Revenue | €1.87m |
| Gross Profit | -€1.45m |
| Other Expenses | €5.52m |
| Earnings | -€6.97m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.32 |
| Gross Margin | -343.30% |
| Net Profit Margin | -1,655.06% |
| Debt/Equity Ratio | 1.8% |
How did 8XX perform over the long term?
See historical performance and comparison